Login to Your Account

Aprea raises $51M in series B for 1st-in-class p53-targeting APR-246

By Cormac Sheridan
Staff Writer

Wednesday, March 9, 2016

DUBLIN – Aprea AB raised €46 million (US$50.7 million) in a series B round that will fund a phase IIb trial in ovarian cancer of its first-in-class p53 reactivator APR-246, as well as a series of exploratory trials in several other oncology indications in which p53 mutations are implicated.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription